Accepted Articles                   Back to the articles list | Back to browse issues page

XML Print

Myasthenia Gravis and COVID-19: A Systematic Review and Meta-Analysis
Amirhossein Nafari1 , Seyedpouzhia Shojaei2 , Reza Jalili Khoshnood3 , Mahsa Ghajarzadeh4 , Arash Tafreshinejad3 , Saeid Safari * 3, Omid Mirmosayyeb5
1- Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
2- Critical Care Quality Improvement Research Center, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3- Functional Neurosurgery Research Center, Shohada Tajrish Neurosurgical Comprehensive Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
4- Multiple Sclerosis Research Center, Neuroscience institute, Tehran University of Medical Sciences, Tehran, Iran.
5- Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract:  
Myasthenia gravis, an autoimmune disease affecting the neuromuscular junction, exhibits varying rates of COVID-19 infection across different studies. This systematic review and meta-analysis aim to estimate the pooled prevalence of COVID-19 infection in individuals with myasthenia gravis(MG). We conducted a systematic search of PubMed, Scopus, EMBASE, Web of Science, Google Scholar, and gray literature, which includes references to the included research that were published prior to October 2021. The total number of participants, the first author,the publication year, the country of origin, the number of MG patients, their symptoms, hospitalization rates, and deaths were all extracted as data. Our literature search yielded 253 articles, of which 75 remained after removing duplicates. Eighteen articles were included in the meta-analysis. The pooled prevalence of COVID-19 infection in MG cases was found to be 2% (95%CI: 1-3%) (I2=85%, P<0.001). Additionally, the pooled prevalence of hospitalization among those with COVID-19 infection was 43% (95%CI: 26-60%) (I2=97.6%, P<0.001), and the pooled prevalence of MG exacerbation was 33% (95%CI: 20-46%) (I2=92.6%, P<0.001). In summary, this systematic review and meta-analysis reveal that the pooled prevalence of COVID-19 infection in individuals with MG is 2%.
Keywords: Myasthenia gravis, COVID-19, Prevalence
Full-Text [PDF 831 kb]      
Type of Study: Review | Subject: Clinical Neuroscience
Received: 2022/08/10 | Accepted: 2022/11/27
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Basic and Clinical Neuroscience

Designed & Developed by : Yektaweb